Even with Jordan and Egypt refusing to take in expelled Palestinians, Trump is charging on with his real estate development plan.
By Jessica Washington and Matt Sledge, The Intercept
President Trump doubled down on his plans to forcibly remove the 2 million Palestinians living in Gaza, though he walked back from his threat to withhold billions in aid to Egypt and Jordan unless they assisted.
Sitting next to Jordanian King Abdullah II at a White House press conference, Trump said he was “above” threatening U.S. allies in order to facilitate his idea of expelling all Palestinians from Gaza. He also promised that taking over Gaza would come at no cost to Americans.
“There’s nothing to buy. We will have Gaza. No reason to buy. There is nothing to buy, it’s Gaza, it’s a war-torn area, we’re going to take it, we’re going to hold it, we’re going to cherish it,” Trump said.
For days, Trump has been repeating his vision of a Gaza free of Palestinians and placed under American control.
The Arab world has rejected the idea — especially the countries that Trump has singled out as potential hosts for the transplanted Palestinian population: Egypt and Jordan.
Recent Posts
Washington, DC, Residents Protest Against Trump
Take Action Now Several thousand protesters march to oppose Trump’s troop deployment Justice Department data shows violent crime at 30-year low…
‘Shameful Assault on Human Rights’: Trump Sanctions Palestinian Orgs That Called for UN to Investigate Israeli War Crimes
Take Action Now The former executive director of Human Rights Watch said Trump’s “answer to Israeli atrocities is to censor reporting on…
Hegseth Doesn’t Rule Out Regime Change In Venezuela, Suggests More U.S. Strikes On Boats Are Coming
Take Action Now When asked if the goal was regime change in Venezuela, Hegseth said that was a “presidential decision” and added that “we’re prepared…
Secretary Kennedy Doesn’t Care About Long COVID Patients
Take Action Now Reckless funding cuts have dealt a significant blow to ongoing research, derailing NIH-funded clinical trials on antivirals and…